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Abstract 
Purpose: To investigate the neuroprotective activity of the aqueous extract of Sutherlandia frutescens 
(SF) against 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in SH-SY5Y neuroblastoma cells. 
Methods: SH-SY5Y neuroblastoma cells were divided into different treatment groups: untreated cells, 
cells treated with MPP+ alone (2 mM), cells pretreated with SF (20 μg) prior to MPP+ (2 mM) treatment 
and cells treated with SF (20 μg) alone. Twenty-four hours after treatment with MPP+, cell viability was 
assessed by MTT assay, and changes in cell morphology, intracellular reactive oxygen species (ROS) 
production, mitochondrial membrane potential (MMP) as well as caspases 3/7 and 9 activities were 
determined. 
Results: Treatment of SH-SY5Y cells with MPP+ alone significantly altered cellular morphology, 
increased ROS production (p = 0.005), induced a significant loss of MMP (p = 0.0011) and caused 
significant apoptotic cell death, via the activation of caspases 3/7 and 9 (p ≤ 0.0359). These effects 
were however significantly (p ≤ 0.0359) attenuated in cells pre-treated with the aqueous leaf extract of 
SF, indicating the possible neuroprotective activity of the SF extract.  
Conclusion: The results of this study suggest that the aqueous leaf extract of SF may be 
neuroprotective against MPP+-induced toxicity via apoptotic cell death and inhibition of ROS production. 
Further mechanistic studies are required to validate the results of the present study using additional PD 
models, different extract preparations and active compounds derived from SF.  
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Parkinson’s disease (PD) is the second most 
common, age-dependent neurodegenerative 
disorder resulting from continuous loss of 
dopaminergic neurons in the pars compacta of 
the substantia nigra of the midbrain (SNpc). 
Resting tremor, bradykinesia and muscle rigidity 
are some of the motor symptoms associated with 
PD, while cognitive and neuropsychiatric 
disorders constitute the non-motor symptoms [1]. 
There is currently no cure for PD, hence the 
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search for effective treatment options capable of 
halting the death of dopaminergic neurons with 
little or no side effects, is plausible. 
 
In order to study the mechanisms involved in PD, 
the standard cellular model of the disease was 
induced using the neurotoxic compound 1-
methyl-4-phenylpyridinium (MPP+), an active 
metabolite of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) was used. When 
MPP+ is taken up by the dopamine transporter, it 
causes damage to dopaminergic neurons in a 
way that is comparable to the mechanisms of the 
human disease [2]. For instance, MPP+ inhibits 
complex I of the mitochondrial electron transport 
chain (ETC), thus diminishing the production of 
ATP and increasing the formation of reactive 
oxygen species (ROS) [2].  
 
Although the etiology and exact molecular 
mechanisms involved in the neuronal 
degeneration observed in PD are poorly 
understood, the involvement of oxidative stress 
(OS), apoptosis and mitochondrial dysfunction 
have been reported. Over the years, research 
has focused more on the pathological importance 
of OS in PD, owing to its role in aging and aging-
related diseases in general. Oxidative stress is 
known to be caused by the imbalance in the 
production of ROS and antioxidants and is 
believed to be a key mechanism that heralds and 
initiates the death of neurons in PD [3]. 
 
Earlier studies have shown substantial evidence 
of oxidative stress in the brains of animal models 
of  PD  [4]. Oxidants are by-products of oxidative 
phosphorylation, thus making mitochondria the 
major sites of ROS generation within the cell. In 
most neurodegenerative diseases characterized 
by mitochondrial respiratory defects, including 
PD, the ROS generated by the ETC increases 
and overwhelms the antioxidant protection 
mechanisms. This is evidenced by post-mortem 
reports of complex I deficiency in the SN of 
individuals with PD, thus establishing a direct link 
between ROS, mitochondrial dysfunction and the 
disease [5]. 
 
Similarly, the vast majority of in vivo and in vitro 
models of PD have been reported to show 
morphological apoptosis and activation of 
caspases [6]. In most of these models, the 
involvement of apoptotic signalling pathways and 
the attenuation of cell death by caspase 
inhibitors tend to support suggestions of 
apoptosis as a mechanism of cell death in PD. 
Thus, it is plausible to investigate antioxidant-rich 
medicinal plants for their apoptosis-inhibiting 
effects as well as their ability to mitigate 
mitochondrial dysfunction and ROS production in 
dopaminergic neurons. Plant extracts with such 
properties could provide potential sources of 
novel therapeutic agents for the protection or 
treatment of PD. 
 
Sutherlandia frutescens (SF), also known as 
‘cancer bush’, is a versatile medicinal plant 
commonly used in South Africa [7]. Its decoctions 
have been used for many years by traditional 
healers to treat open wounds, inflammation, 
fever, eye infections, chicken pox and 
haemorrhoids [8]. It is also consumed as a herbal 
remedy by individuals living with HIV/AIDS in 
South Africa as an immune-booster and to 
improve general well-being [9].  
 
Various studies have investigated the beneficial 
effects of SF in cancer [10], diabetes [11] and 
inflammation [12]. Phytochemical evaluations of 
this plant have shown that it contains significant 
amounts of pharmacologically important 
constituents, including gamma-aminobutyric acid, 
glycosides, saponins, and L-canavanine. 
Although SF has been reported to show activity 
in various disease models, studies on its 
neuroprotective activity in a Parkinson’s disease 
model have not been reported.  This study 
therefore investigated the mechanisms by which 
SF could potentially provide neuroprotection 
against MPP+-induced cell death in the SH-SY5Y 
human neuroblastoma cell line used as a model 




Preparation of extract 
 
Dry-milled leaf powder of SF (variety Incana E. 
Mey.) [Family: Fabaceae] was purchased from 
Big Tree Health Products (Fish Hoek, South 
Africa). To prepare the aqueous extract of the 
plant, 1 kg of the leaf powder was added to 
boiling water and incubated overnight. The 
extract was then filtered with Whatman filter 
paper and freeze-dried to yield the aqueous 
extract which was stored at -20°C until needed. 
 
Cell culture maintenance 
 
SH-SY5Y cells were maintained in Dulbecco’s 
modified Eagle medium (DMEM) (Life 
Technologies, USA), supplemented with 10% 
Fetal bovine serum (FBS) (Life Technologies, 
USA) and 1% penicillin-streptomycin (Lonza, 
USA), at 37 °C, 5% CO2 in a humidified 
incubator. The culture medium was changed 
every two days and the cells were trypsinized 
with 1X trypsin-versene EDTA mixture (Lonza, 
USA) and transferred to a different dish for 
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regrowth once a confluency of 70 - 80 % was 
reached. 
 
Cytotoxicity screening, cell viability and 
toxicity assay 
 
Cytotoxicity screening was performed to ensure 
that SH-SY5Y cells were exposed to the correct 
concentrations of MPP+ and SF. A fresh stock 
concentration of MPP+ was prepared on the day 
of the experiment and dilutions were made up for 
final concentration ranges of 0 – 4000 μM. For 
SF, a fresh stock concentration was prepared on 
the day of the experiment and dilutions were 
made up for final concentration ranges of 0 – 60 
μg. Cell viability was determined using MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, St. Louis, MO, USA] assay [13, 14]. 
SH-SY5Y cells, seeded at a density of 1.0 x 104 
cells/well in 96-well plates, were allowed to 
attach for 24 h. Based on the findings from the 
cytotoxicity screening, cells were pretreated with 
20 μg of SF for 1 h and then treated with 2000 
μM of MPP+ for 24 h. Thereafter, 20 μL of the 
MTT solution was added to each well of the plate 
and incubated for 3 h. Absorbance was 
measured at a wavelength of 560 nm using the 
Glomax Multi Detection System (Promega, USA).  
 
The trypan blue (TB) dye exclusion assay was 
used to measure toxicity in treated and untreated 
samples. The TB dye only enters non-viable cells 
through their damaged cell membranes while 
healthy viable cells exclude this dye. For this 
assay, the SH-SY5Y cells were seeded at a 
density of 1.1 x 105 /ml in 60 mm dishes and 
treated as previously described. Adherent cells 
were detached by trypsinization, pelleted and re-
suspended in fresh culture media. A 20 μL of the 
cell suspension was added to an equivalent 
volume of 0.4 % trypan blue dye (Sigma Aldrich, 
St. Louis, MO, USA) and loaded into a BioRad 
TC20TM automated cell counter. Toxicity was 
expressed as the percentage of dead cells 
relative to the total cell count. 
 
Morphological evaluation of cells 
 
The SH-SY5Y cells were seeded at a density of 
1.1 x 105 /mL in 60 mm dishes and were allowed 
to attach for 24 h. The cells were treated as 
earlier described and morphological changes 
were observed using a ZEISS Primo Vert 
(Germany) light microscope. 
 
Determination of reactive oxygen species 
production 
 
The production of reactive oxygen species was 
determined using the 2′,7′-dichlorofluorescin 
diacetate (DCFH-DA, St. Louis, MO, USA) dye. 
The SH-SY5Y cells were seeded at a density of 
1.2 x 105 /mL in 100 mm dishes and treated as 
previously described. After treatment, adherent 
cells were dislodged with a scrapper and spun 
using a Bio-Rad tabletop centrifuge at 3000 rpm 
for 5 min. Cell pellets were resuspended and 
incubated with 25 μM of DCFH-DA for 45 min. 
Stained cells were pelleted, resuspended in PBS 
(500 μL) and thereafter analysed on an Accuri 
flow cytometer (BD Biosciences Pharmingen, 
San Diego, CA, USA), with a total of 10000 
events acquired for each sample. 
 
Determination of mitochondrial membrane 
potential 
 
Mitochondrial membrane potential was 
determined using rhodamine 123 (St. Louis, MO, 
USA) fluorescence dye. The SH-SY5Y cells were 
seeded at a density of 1.2 x 105 /mL and were 
treated as previously described. Thereafter, 
adherent cells were dislodged with a cell scraper 
and spun at 3000 rpm for 5 min. Cell pellets were 
resuspended and incubated with 10 μM of 
rhodamine123 for 30 min. Stained cells were 
pelleted, resuspended in PBS (500 μL) and 
thereafter analysed on an Accuri flow cytometer 
(BD Biosciences Pharmingen, San Diego, CA, 
USA), with a total of 10000 events acquired for 
each sample. 
 
Evaluation of Caspase 3/7 and Caspase 9 
activities 
 
The ApoTarget™ Caspase-9 Protease Assay 
(Life Technologies, USA) was used to evaluate 
the activity of caspase-9. SH-SY5Y cells were 
seeded at a density of 1.2 x 105 cells /mL in 100 
mm dishes and treated as earlier described. 
Adherent cells were displaced, pelleted, re-
suspended in lysis buffer and incubated on ice 
for 10 min. Experiments were performed 
according to the manufacturer’s instructions, and 
absorbance was detected using a Polarstar 
Omega plate reader (BMG Labtech, USA) at 405 
nm. Also, the Caspase 3/7 assay kit (Promega, 
USA) was used to evaluate the activity of 
caspase 3/7. SH-SY5Y cells were seeded at a 
density of 1.0 x 104 cells/well in white-walled 96-
well plates and treated as earlier described. After 
treatment, experiments were performed 
according to the manufacturer’s instructions, and 
luminescence was measured using the Glomax 




Statistical analyses were done using the 
GraphPad Prism Software V7 
Enogieru et al 
Trop J Pharm Res, March 2020; 19(3): 552 
 
(www.graphpad.com/scientific-software/prism/), 
and data expressed as mean with standard error 
of mean (SEM) from three independent 
experiments. One-way analysis of variance 
(ANOVA) followed by Tukey's multiple 
comparisons post-hoc test was used to analyze 
the relationship between variables. Significance 




Dose-response of MPP+ and SF toxicity.  
 
Cell viability significantly decreased following a 
24-h incubation of the SH-SY5Y cells with 
increasing concentrations of MPP+ (0 - 4000 
µM). The dose-response investigation was done 
to determine the MPP+ concentration which will 
result in approximately 50 % viable cells (Figure 
1A). For SF, there was a significant increase in 
cell viability after 24-h treatment with increasing 
concentrations of the SF extract (20 - 60 µg). 
Consequently, a concentration of 20 μg was 
chosen for use in further experiments based on 
the highest absorbance value (p = 0.0008, Figure 
1 B). 
 
Effect of SF on MPP+-induced toxicity in SH-
SY5Y cells 
 
The MTT assay results (Figure 1C) showed that 
treatment with MPP+ alone caused a significant 
decrease in cell viability (p < 0.0001), while 
pretreatment with SF before exposure to MPP+ 
resulted in significant increase (p = 0.0008,) in 
cell viability. In the SH-SY5Y cells treated with 
SF alone, cell viability was not significantly 
different (p = 0.4204) when compared to the 
viability of the untreated cells. Similarly, results of 
the trypan blue dye exclusion assay revealed 
that treatment with MPP+ alone caused a 
significant increase in cell toxicity (p = 0.0004), 
while pretreatment with SF significantly 
decreased (p = 0.0016, Figure 1 D) cell toxicity. 
When compared to the untreated SH-SY5Y cells, 
the toxicity observed in SH-SY5Y cells treated 
with SF alone was not statistically significant (p = 
0.9511). 
 
Morphology of SH-SY5Y cells following SF 
pretreatment 
 
Morphological evaluation of the SH-SY5Y cells 
treated with MPP+ alone showed shrinkage and 
rounding up of cell bodies while SF pre-treatment 
appeared to have prevented these MPP+-
induced morphological alterations. On the other 
hand, the morphology of cells exposed to SF 
alone appeared similar to that of the untreated 




Figure 1: Effect of treatment with SF extract on MPP+-
induced toxicity in SH-SY5Y cells. (A) MPP+ toxicity 
screening (B) SF toxicity screening (C) MTT cell 
viability assay (D) Trypan blue dye exclusion assay. 
p < 0.0005 vs untreated SH-SY5Y cells; *p < 0.05 vs 




Figure 2: Effects of treatment with SF extract on 
MPP+-induced morphological alterations in SH-SY5Y 
cells. (A) Untreated SH-SY5Y cells (B) SH-SY5Y cells 
treated with MPP+ alone (C) SH-SY5Y cells pretreated 
with SF and then treated with MPP+ (D) SH-SY5Y 
cells treated with SF only. Arrows indicate shrinking 
and contracting SH-SY5Y cells. Scale bar: 5μm 
 
ROS production following SF pretreatment 
 
Whereas ROS levels significantly increased (p = 
0.005) in SH-SY5Y cells treated with MPP+ 
alone, pretreatment with SF significantly reduced 
(p = 0.0316) ROS production. However, there 
was no significant difference (p = 0.994) in the 
ROS levels in the SH-SY5Y cells treated with SF 
alone when compared to the untreated cells 
(Figure 3). 
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Figure 3: Effects of treatment with SF extract on 
MPP+-induced ROS production. (A) Untreated vs 
MPP+ alone (B) SF pretreated vs MPP+ alone (C) 
Untreated vs SF alone (D) Bar chart showing the 
effect of SF on ROS production. Arrows indicate 
fluorescence intensity of cells treated with MPP+ only. 
p < 0.0005 vs untreated SH-SY5Y cells; *p < 0.05 vs 
SH-SY5Y cells treated with MPP+ only 
 
Mitochondrial membrane potential in SH-




Figure 4: Effects of treatment with SF extract on 
MPP+-induced loss of MMP. (A) Untreated vs MPP+ 
alone (B) SF pretreated vs MPP+ alone (C) Untreated 
vs SF alone (D) Graph showing the effect of SF on 
MMP. Arrows indicate fluorescence intensity of cells 
treated with MPP+ only. p < 0.005 vs untreated SH-
SY5Y cells; *p < 0.005 vs SH-SY5Y cells treated with 
MPP+ only 
 
The reduction of rhodamine 123 fluorescence 
intensity signifies a loss of MMP. The graphs in 
Figure 4 showed that MPP+ treatment alone 
significantly reduced (p = 0.0011) the MMP as 
demonstrated by a shift to the left in the 
fluorescence intensity while treatment with the 
SF extract appeared to inhibit (p = 0.0025) the 
MPP+-induced reduction in MMP. On the other 
hand, treatment with SF alone did not 
significantly affect (p = 0.8877) the MMP when 
compared to untreated SH-SY5Y cells. 
 
Caspase 3/7 and 9 activities following SF 
pretreatment 
 
The SH-SY5Y cells treated with MPP+ alone 
showed that caspase 3/7 (p = 0.0006) and 
caspase 9 (p = 0.0011) activities were 
significantly increased, which is an indication of 
the activation of apoptosis (Figure 5). In cells 
pretreated with SF, there was a significant 
decrease in the activities of caspase 3/7 (p = 
0.0199) and caspase 9 (p = 0.0359) respectively. 
Treatment with SF alone did not significantly 
affect caspase 3/7 (p = 0.9184) and 9 (p = 





Figure 5: Effects of treatment with SF extract on 
MPP+-induced apoptosis. (A) Caspase 3/7 activity (B) 
Caspase 9 activity. p < 0.005 vs untreated SH-SY5Y 





This study demonstrated the neuroprotective 
activity of SF in an in vitro model of PD using the 
neurotoxin MPP+ and dopaminergic SH-SY5Y 
human neuroblastoma cells. Exposure of SH-
SY5Y cells to MPP+ for 24 h significantly 
decreased cell viability, increased toxicity, 
increased intracellular ROS production, induced 
loss of MMP and activated caspases 3/7 and 9. 
However, the changes induced by MPP+ were 
significantly inhibited by pretreatment of the SH-
SY5Y cells with SF, which suggests that SF may 
protect the cells from MPP+-induced apoptosis 
and loss of MMP via the regulation of ROS. 
 
Previous studies have indicated that in PD 
patients, about 50 % of dopaminergic neurons in 
the nigrostriatal pathway have degenerated in 
the brain at the time of preliminary diagnosis, and 
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a substantial portion of the remaining 
dopaminergic neurons are stressed [15,16]. In a 
bid to replicate this condition in this model of PD, 
it was imperative to utilize concentrations of 
toxins that induced approximately 50 % cell 
death. Findings from the MTT assay showed that 
the selected dose of MPP+ treatment induced 
approximately 50 % cell death, which is in line 
with earlier studies indicating that treatment of 
cells to high concentrations of MPP+ for 24 h 
result in a mix of healthy and unhealthy cell 
population [17,18]. Findings from this study also 
show that pretreatment of SH-SY5Y cells with SF 
protected the cells from MPP+-induced toxicity. 
From the morphological images, it was observed 
that the shrinkage of cell bodies and the 
disappearance of axons were evident in the 
MPP+-treated cells, whereas cells pretreated with 
the SF extract looked similar to the untreated 
cells.   
 
The pathogenesis of PD has been reported to 
involve excessive production of ROS and the 
ability of many medicinal plant extracts to reverse 
or modulate excess ROS is a known 
neuroprotection mechanism. MPP+ is a known 
ROS-inducing neurotoxin, and overproduction of 
ROS has been reported to contribute to oxidative 
damage, mitochondrial dysfunction and apoptotic 
cell death [19]. One of the mechanisms reported 
for the excessive production of intracellular ROS 
by MPP+ is the inhibition of the mitochondrial 
electron transport chain complex I [20]. This 
excessive production of intracellular ROS is 
believed to be an early event preceding the 
activation of caspase-9 as well as caspase-3/7, 
leading to apoptosis [21]. These events show 
that ROS is a key player in cellular apoptosis 
induced by MPP+. The results further revealed 
that intracellular ROS production significantly 
increased following treatment of SH-SY5Y cells 
with MPP+. Conversely, intracellular ROS 
production significantly reduced when SH-SY5Y 
cells were pretreated with SF before MPP+ 
treatment. 
 
Mitochondria are susceptible to oxidative stress 
and when there is sustained generation of ROS, 
there may be alterations in mitochondrial 
morphology, which further results in the opening 
of the mitochondrial transition pore, and a loss of 
MMP [19]. A reduction in membrane potential is 
an indicator of early apoptosis, and is consistent 
with previous findings. The results from the 
current study showed that SH-SY5Y cells 
displayed a decline in mitochondrial membrane 
potential upon treatment with MPP+. Conversely, 
pretreatment with SF prevented the loss of MMP 
which may suggest a neuroprotective effect of 
SF against MPP+-induced toxicity.  
In the pathogenesis of PD, both the extrinsic 
(death-receptor) and the intrinsic (or 
mitochondrial) apoptotic pathways are known to 
play major roles. Investigations on the events 
involved in the intrinsic pathway show that 
cytochrome c binds to the apoptosis protease 
activating factor 1 (Apaf-1) in the cytoplasm to 
form an apoptosome (a molecular complex 
consisting of cytochrome c, Apaf-1, ATP, and 
procaspase 9). The apoptosome in turn activates 
caspase 9 (an upstream initiator of apoptosis) 
which then activates the executioner caspases 3, 
6 and 7, eventually resulting in apoptosis [22]. In 
the present study, the activity of caspases 3/7 
and 9 significantly increased in SH-SY5Y cells 
treated with MPP+ alone. However, pretreatment 
of cells with SF significantly inhibited the activity 
of these caspases, indicating that SF inhibited 





The findings of the current study demonstrate the 
neuroprotective activity of the SF extracts against 
MPP+-induced toxicity in SH-SY5Y cells. The SF 
extracts appeared to inhibit MPP+-induced 
overproduction of ROS as well as a loss of MMP. 
These extracts could attenuate the activation of 
the intrinsic apoptotic pathway, thus suggesting 
the potential use of the plant as a 
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